Kadcyla Prices, Coupons, Copay Cards & Patient Assistance
Kadcyla (ado-trastuzumab emtansine) is a member of the HER2 inhibitors drug class and is commonly used for Breast Cancer, and Breast Cancer - Metastatic.
The cost for Kadcyla 100 mg intravenous powder for injection is around $4,148 for a supply of 1 powder for injection, depending on the pharmacy you visit. Quoted prices are for cash-paying customers and are not valid with insurance plans. This price guide is based on using the Drugs.com discount card which is accepted at most U.S. pharmacies.
Kadcyla prices
Intravenous Powder For Injection
100 mg
Kadcyla intravenous powder for injection
from $4,148.49
for 1 powder for injection
Quantity | Per unit | Price |
---|---|---|
1 | $4,148.49 | $4,148.49 |
Important: When there is a range of pricing, consumers should normally expect to pay the lower price. However, due to stock shortages and other unknown variables we cannot provide any guarantee.
160 mg
Kadcyla intravenous powder for injection
from $6,631.88
for 1 powder for injection
Quantity | Per unit | Price |
---|---|---|
1 | $6,631.88 | $6,631.88 |
Important: When there is a range of pricing, consumers should normally expect to pay the lower price. However, due to stock shortages and other unknown variables we cannot provide any guarantee.
Drugs.com Printable Discount Card
The free Drugs.com Discount Card works like a coupon and can save you up to 80% or more off the cost of prescription medicines, over-the-counter drugs and pet prescriptions.
Print Free Discount CardNote: This is a drug discount program, not an insurance plan. Valid at all major chains including Walgreens, CVS Pharmacy, Target, WalMart Pharmacy, Duane Reade and 65,000 pharmacies nationwide.
Kadcyla Coupons, Copay Cards and Rebates
Kadcyla offers may take the form of printable coupons, rebates, savings or copay cards, trial offers, or free samples. Certain offers may be printable from a website while others may require registration, completing a questionnaire, or obtaining a sample from a medical professional.
Kadcyla Genentech Oncology Co-pay Assistance Program
Eligible commercially insured patients may pay $0 in out-of-pocket costs for the prescribed product; savings of up to $25,000 per product per calendar year; for additional information contact the program at 855-692-6729.
- Applies to:
- Kadcyla
- Number of uses:
- Per prescription per calendar year
Form more information phone: 855-692-6729 or Visit website
Kadcyla Genentech Oncology Co-pay Assistance Program Rebate
Eligible commercially insured patients enrolled in the program may be entitled to a rebate for their out-of-pocket cost if they paid the provider directly for treatment; for additional information contact the program at 855-692-6729.
- Applies to:
- Kadcyla
- Number of uses:
- One rebate per prescription fill
Form more information phone: 855-692-6729 or Visit website
Patient Assistance & Copay Programs for Kadcyla
Patient assistance programs (PAPs) are typically sponsored by pharmaceutical companies and offer cost-free or discounted medicines, as well as copay programs, to individuals with low income or those who are uninsured/under-insured and meet specific criteria. Eligibility requirements for each program may vary.
Provider: Patient Access Network Foundation (PAN)
Eligibility requirements:- *See Additional Information section below
- Between 400-500% of FPL
- FDA Approved Diagnosis - See Program Website for Details
- Must reside and receive treatment in US
- *Patients must have health insurance and their insurance must cover the qualifying medication for which they seek assistance. Call for most recent medications as the list is subject to change and the medication for which you are seeking assistance must treat the disease directly. Note: All new enrollment is now done electronically or over the phone. Contact program for details.
- Kadcyla (ado-trastuzumab emtansine) Injection; IV
More information please phone: 866-316-7263 Visit Website
Provider: Genentech Oncology Access Solutions
Eligibility requirements:- Determined case by case
- Based on FPL
- Varies
- Must be treated by US licensed healthcare provider
- Call for most recent medications as the list is subject to change. Eligibility determined on a case-by-case basis. Contact program for details.
- Kadcyla (ado-trastuzumab emtansine) Injection; IV
More information please phone: 888-249-4918 or 866-422-2377 Visit Website
Provider: Genentech Patient Foundation
Eligibility requirements:- Uninsured or Underinsured with no prescription coverage for needed medication
- Based on FPL
- Medically appropriate condition/diagnosis
- Must be treated by US licensed healthcare provider
- The Genentech Access to Care Foundation is now the Genentech Patient Foundation. Eligibility determined on a case-by-case basis. Call for most recent medications as the list is subject to change. This program may provide a Bridge Program for eligible patients who experience a delay, temporary loss, or change in coverage. Contact program for details.
- Kadcyla (ado-trastuzumab emtansine) Injection; IV
More information please phone: 888-941-3331 or 866-422-2377 Visit Website
Disclaimer: Medication pricing is sourced from a variety of providers. Pricing may vary significantly due to several factors including brand or generic status, insurance coverage, pharmacy choice, location, and manufacturer pricing policies. Prices are subject to change. For the most accurate and up-to-date information, always consult directly with your pharmacy or healthcare provider.
More about Kadcyla (ado-trastuzumab emtansine)
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: HER2 inhibitors
- Breastfeeding
- En español